{
    "clinical_study": {
        "@rank": "43350", 
        "arm_group": {
            "arm_group_label": "Isavuconazole and warfarin", 
            "arm_group_type": "Experimental", 
            "description": "Isavuconazole three times daily (TID)  for 2 days followed by once daily (QD) dosing for 11 days and warfarin single doses on Days 1 and 20"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the effect of multiple doses of isavuconazole on the\n      pharmacokinetics (PK) of warfarin after single dose administration."
        }, 
        "brief_title": "Drug Interaction Study of Isavuconazole and Warfarin in Healthy Male Subjects", 
        "completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Pharmacokinetics of Isavuconazole", 
            "Pharmacokinetics of S- and R-warfarin", 
            "Pharmacodynamics of Warfarin", 
            "Healthy Volunteers"
        ], 
        "detailed_description": {
            "textblock": "Subjects will receive a single dose of warfarin on Day 1 followed by a 15 day wash-out\n      period (time from warfarin dosing to isavuconazole dosing).\n\n      On Days 16 and 17, isavuconazole  will be dosed three times daily (TID). TID doses will be\n      administered 8 hours apart. On Days 18 through 28, isavuconazole  will be administered once\n      daily (QD). All subjects will be administered a single dose of warfarin on Day 20. A follow\n      up visit will occur approximately 7 days after the last dose of isavuconazole.  Blood\n      samples for pharmacokinetics will be collected throughout the study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have BMI of 18 to 32 kg/m2 and a body weight of at least 45 kg\n\n          -  Subjects  must have normal laboratory values especially for ALT, AST, protein C and\n             S, and prothrombin time\n\n        Exclusion Criteria:\n\n          -  The subject has a history of unexplained syncope, cardiac arrest, unexplained cardiac\n             arrhythmia or torsade de pointes, structural heart disease, or family history of Long\n             QT syndrome (suggested by sudden death of a close relative at a young age due to\n             possible or probable cardiac causes)\n\n          -  The subject has a positive result for hepatitis C antibodies or hepatitis B surface\n             antigen at Screening or is known to be positive for human immunodeficiency virus\n             (HIV)\n\n          -  The subject has a known or suspected allergy to any of the components of the trial\n             products or the azole class of compounds, or a history of multiple and/or severe\n             allergies to drugs or foods (as judged by the investigator), or a history of severe\n             anaphylactic reactions\n\n          -  The subject is a smoker (any use of tobacco or nicotine containing products) within 6\n             months prior to Screening\n\n          -  The subject has had treatment with prescription drugs or complementary and\n             alternative medicines within 14 days prior to Day -1, or over-the-counter medications\n             within 1 week prior to Day -1\n\n          -  The subject has received an experimental agent within 30 days or 5 half-lives,\n             whichever is longer prior to Day -1\n\n          -  The subject has a recent history (within the last 2 years) of drug or alcohol abuse,\n             as defined by the investigator, or a positive drug and/or alcohol screen"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01657825", 
            "org_study_id": "9766-CL-0033"
        }, 
        "intervention": [
            {
                "arm_group_label": "Isavuconazole and warfarin", 
                "description": "oral", 
                "intervention_name": "Isavuconazole", 
                "intervention_type": "Drug", 
                "other_name": "BAL8557"
            }, 
            {
                "arm_group_label": "Isavuconazole and warfarin", 
                "description": "oral", 
                "intervention_name": "Warfarin", 
                "intervention_type": "Drug", 
                "other_name": "Coumadin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Warfarin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "isavuconazole", 
            "warfarin", 
            "Healthy Volunteers", 
            "BAL8557", 
            "Coumadin"
        ], 
        "lastchanged_date": "August 27, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Bend", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53095"
                }, 
                "name": "Spaulding Clinical"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1, Open-Label, Sequential Study of the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of a Single Dose of Warfarin in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Astellas Pharma Global Development", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Area under the curve (AUC) from time 0 extrapolated to infinity (AUCinf), AUC from time of dosing to last quantifiable concentration (AUClast ), and maximum concentration (Cmax)", 
            "measure": "Composite of  Pharmacokinetic (PK) variables for   S-warfarin (in plasma): AUCinf, AUClast, Cmax", 
            "safety_issue": "No", 
            "time_frame": "Days 1 and 20, predose  and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,16, 24, 48, 72, 96, 120, 144, 168, and 216 hours postdose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01657825"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Composite  of  PK variables for R-warfarin (in plasma): AUCinf, AUClast, Cmax", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 20, predose  and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,16, 24, 48, 72, 96, 120, 144, 168, and 216 hours postdose"
            }, 
            {
                "description": "Time to attain Cmax (tmax) , apparent volume of distribution  (Vz /F), apparent body clearance after oral dosing (CL/F), and apparent terminal elimination half-life (t1/2)", 
                "measure": "Composite of  Pharmacokinetic (PK) variables for S-warfarin and R-warfarin (in plasma): tmax, Vz /F, CL/F, and  t1/2", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 20, predose and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12,16, 24, 48, 72, 96, 120, 144, 168, and 216 hours postdose"
            }, 
            {
                "measure": "PK variable for isavuconazole (in plasma): trough concentration (Ctrough)", 
                "safety_issue": "No", 
                "time_frame": "Days 18-20 and Days 22-27, predose and Day 28 predose and 24 hours post dose"
            }, 
            {
                "description": "AUC during the time interval between consecutive dosing (AUCtau)", 
                "measure": "Composite of PK variable for isavuconazole (in plasma): AUCtau , Cmax, and  tmax", 
                "safety_issue": "No", 
                "time_frame": "Day 19 predose and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 16 hours post dose; and Day 20, predose and at 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 36 hours postdose"
            }, 
            {
                "description": "International Normalized Ratio (INR), Maximum observed change INR value (MAXINR), Area under the INR time curve from 0 to 216 hours (AUCINR), Maximum observed change in prothrombin time (PT)value (MAXPT), Area under the PT time curve from 0 to 216 hours (AUCPT)", 
                "measure": "Pharmacodynamic Variables: MAXINR, AUCINR, MAXPT, and AUCPT", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Day 20 predose and at 6, 12, 24, 48, 72, 96, 168, and 216 hours post-warfarin-dose"
            }, 
            {
                "measure": "Safety assessed by recording of adverse events, clinical laboratory evaluation, electrocardiograms (ECGs) physical examinations, and vital signs", 
                "safety_issue": "No", 
                "time_frame": "Day 1 through Day 29, Day 35 \u00b1 2"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Basilea Pharmaceutica International Ltd", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Global Development, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}